Drug intelligence / Profile preview

Rincell-3

Development stage: Preclinical
Lead developer: Rinri Therapeutics
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Otic

Overview

Rincell-3 is a preclinical-stage cell therapy developed by Rinri Therapeutics for the treatment of sensorineural hearing loss. The therapeutic approach involves the use of human pluripotent stem cell-derived human otic epithelial progenitor cells (hPSC-hOEPs) to replace damaged or missing auditory hair cells within the cochlea. By regenerating these sensory cells, Rincell-3 aims to restore the transduction of sound into electrical signals, addressing a primary cause of hearing impairment. This program is distinct from the company's lead asset, Rincell-1, which targets the replacement of auditory neurons.

Other names: Rincell 3Rincell3Rincell-3Rincell-3: Auditory Hair Cell (hPSC-hOEPs)

Beyond the preview

Go deeper on Rincell-3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rincell-3.

Explore the full profile